Teva exec granted 141,478 restricted share units

Teva Pharmaceutical Industries Ltd. reported that Exec.

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd. reported that Exec. VP, European Commercial, Richard Daniell was granted 141,478 restricted share units (RSUs) on January 27, 2026. Each RSU represents a right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.

The RSUs were earned upon satisfaction of performance criteria tied to earlier performance share units and remain subject to time-based vesting. They are scheduled to vest on March 3, 2026. The underlying ordinary shares may be represented by American Depositary Shares, with each ADS currently equal to one ordinary share.

Insider Trade Summary

Grant/Award: 141,478 shares

Grant/Award 1 txn

Insider Daniell Richard

Role Exec. VP, European Commercial

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	141,478	$0.00	$0.00

Holdings After Transaction: Restricted Share Units — 141,478 contracts (Direct)

Footnotes (3)

1. F1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
2. F2. Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026.
3. F3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Teva (TEVA) report for Richard Daniell?

Teva reported that Exec. VP, European Commercial, Richard Daniell was granted 141,478 restricted share units on January 27, 2026. These units were earned after performance criteria were met and remain subject to time-based vesting until March 3, 2026.

How many Teva (TEVA) restricted share units were granted in this Form 4?

The filing shows a grant of 141,478 restricted share units (RSUs). Each RSU represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share, subject to the vesting schedule described in the filing.

When do the reported Teva (TEVA) restricted share units vest?

The restricted share units reported for Richard Daniell will vest on March 3, 2026. They were received after performance criteria for earlier performance share units were satisfied and then became subject to this additional time-based vesting requirement before settlement.

What do Teva (TEVA) restricted share units represent for this insider award?

Each Teva restricted share unit represents a contingent right to receive, at settlement, one ordinary share or the cash value of one ordinary share. The Human Resources and Compensation Committee may decide whether settlement occurs in shares or cash, as noted in the filing.

How are Teva (TEVA) ordinary shares related to American Depositary Shares in this filing?

The filing explains that Teva ordinary shares may be represented by American Depositary Shares (ADSs). It states that each ADS currently represents one ordinary share, so the RSUs effectively relate to the same underlying economic interest as a single ADS per ordinary share.

Is the Teva (TEVA) Form 4 transaction a purchase or a grant?

The Form 4 records an “A” (acquisition) transaction code for restricted share units, reflecting an equity award rather than an open-market purchase. The RSUs were granted after performance criteria were met and continue to be subject to time-based vesting until March 3, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/29/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daniell Richard

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Exec. VP, European Commercial

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	01/27/2026		A		141,478		(2)	(2)	Ordinary Shares(3)	141,478	$0	141,478	D

Explanation of Responses:

1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

2. Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026.

3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

	/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.